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Abstract: Today, fewer children die each year from vaccine-preventable diseases than older adults.
Health systems need new immunization strategies to tackle the burden of vaccine-preventable disease
in an aging society. A life-course immunization (LCI) approach—which entails vaccination throughout
an individual’s lifespan—enables adults to age with reduced risk to disease, thereby enabling healthy,
active and productive aging. We conducted an audience response system (ARS)-based survey to
investigate HCP perspectives on LCI in an opportunistic sample of 222 health care professionals (HCPs)
from around the world who attended a European infectious diseases conference. Survey results
show that LCI is a priority for HCPs (77.4%–88.6%), with most of them stating the need to frame
it as a part of a healthy lifestyle (91.0%–100.0%). Insufficient LCI recommendations by vaccine
providers (12.9%–33.3%) and governments (15.2%–41.9%) and insufficient targeted budget allocation
(6.1%–21.7%) were indicated as the main barriers to implement LCI, ahead of vaccine hesitancy
(9.7%–15.2%). HCPs were willing to make LCI a gateway to healthy aging but need support to work
together with other stakeholders involved in the vaccination journey. This could be a step towards
equitable health care for all of society.
Keywords: life-course immunization (LCI); healthy aging; vaccine confidence; vaccination behavior;
audience response system (ARS) survey
1. Introduction
Worldwide, average life expectancy has rapidly increased from 66.5 years in 2000 to 72.0 years
in 2016, with an increasing trend predicted for the next decades [1]. By 2030, almost 1 billion
people will be over 65 years of age and, for the first time in history, this age group will outnumber
children below the age of five years [2]. There is no precedent in history for a society with this
demographic structure and health care systems will need new policies to provide care for a society
with an aging profile [2]. The World Health Organization (WHO) has recommended health-promotion
and disease-prevention strategies to maintain the health and independence of this aging population [3].
Strategies such as national immunization programs have contributed greatly to the increase in life
expectancy by reducing the burden of infectious diseases over the last century [4]. Despite these
efforts, immunization rates in adolescents and adults remained below recommended targets in many
countries [5]. Specifically, the uptake and optimization of maternal immunization—vaccination which
protects pregnant women and newborns against vaccine-preventable diseases—deserves special
attention [6]. Maternal immunization is the only immunization strategy that directly benefits two
generations through a single preventive intervention. Still, the worldwide implementation of maternal
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immunization has remained suboptimal [7]. Furthermore, the WHO also recommends routine
immunization for healthy adolescents (e.g., human papillomavirus vaccine for adolescents) and adults
(e.g., seasonal influenza vaccine), timely receipt of the booster dose (e.g., tetanus toxoid, reduced
diphtheria toxoid and acellular pertussis [Tdap] and meningitis) and catch-up vaccinations if routine
immunization during childhood was missed (e.g., the measles, mumps, rubella or varicella vaccine) [8].
Despite these recommendations, global vaccine uptake remains below recommended levels [9,10].
Considering this situation, experts and institutions recommend extending the vaccine prevention
strategy to a “life-course” approach that places emphasis on the need for vaccination against
vaccine-preventable diseases through all stages of an individual’s lifespan [11]. This vaccination
strategy is called life-course immunization (LCI) [12,13]. The LCI approach enables individuals to age
better by reducing the burden of vaccine-preventable infectious diseases [12]. Despite this significant
potential and the endorsement by the WHO, LCI has not yet become a priority on national health
agendas [14]. A limitation of this approach could be that since the term is loosely defined, the benefits
of adopting LCI may not be easily perceived or may depend on the specifics of the vaccination
program [15]. Barriers to LCI include the lack of established vaccination delivery strategies in all
age groups and the negatively perceived safety and effectiveness of vaccination [16]. Low vaccine
coverage and a lack of vaccine knowledge (beyond childhood vaccination) among the general public
and health care professionals (HCPs) create additional barriers [16]. Published literature suggests that
HCP attitudes and recommendations play an important role in vaccination uptake among individuals
of all ages [12]. Therefore, it is crucial to understand their attitudes towards LCI. We conducted an
audience response system (ARS)-based survey to investigate HCP perspectives on LCI.
2. Materials and Methods
This work was presented in part at a satellite symposium on LCI held at the 35th European Society
of Paediatric Infectious Disease (ESPID) conference in Madrid, Spain in 23–27 May 2017. We conducted
a survey of an opportunistic sample of 222 health care professionals (HCPs) from around the world,
who were among the attendees of the satellite symposium on LCI.
The LCI symposium participants were not asked about their locations of origin. Hence,
demographic information on the participants could only be estimated from the overall conference
participants. Out of 3039 overall conference participants, the majority came from Europe (68%) and
East Asia and Pacific (10%) regions. The remaining participants were from Central and South America
(7.0%), Middle East (5.0%), North America (5.0%), Africa and Atlantic (2.0%) and Central Asia (2.0%).
Spain (18.0%) and United Kingdom (11.0%) were the most represented countries among the participants
of the conference. Other countries represented among the participants were France, Belgium, Greece,
Portugal, Romania, Lebanon, Germany, Brazil, Italy, Pakistan, Russia, Switzerland, The Netherlands,
Austria, Bangladesh, India and Turkey.
Professional interests of the conference participants were represented under five
categories—namely, pediatrics (43.0%), pediatric infectious diseases (38.0%), infectious disease (8.0%),
public health and preventive medicine (7.0%) and microbiology (4.0%). Participants identified their
professional roles as clinical practitioner (35.0%), resident/research fellow (14.0%), clinical researcher
(14.0%), industry/corporate professional (13.0%), other (10.0%) and student (10.0%). The remaining
participants identified basic science researchers (3.0%) and nurse/health care practitioners (1.0%) as
their professional role.
2.1. Participants
An open invitation to attend the satellite symposium at the ESPID 2017 conference was circulated
through the conference website and at the conference venue. Out of the 3039 individuals who
attended the ESPID 2017 conference, 222 HCPs participated in the symposium. There were no
exclusion criteria for the HCPs participating in the survey and participation was voluntary. However,
144 industry representatives who participated in the survey were excluded from the post-event analysis.
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No incentives were offered for attendance or participation in the survey. Consent to participate in
the anonymized survey and to use the collected data for analyses was obtained at the outset of the
electronic survey. Participants responded to questions that appeared on the central display, after the
lectures of experts in the field of LCI and prior to the open Question & Answer session (Q&A).
No personal details were asked for or recorded other than the participant’s profession.
The question on participant profession was asked as a multiple-choice question with five choices
(pediatrician/pediatrician subspecialist, infectious disease clinician, public health professional, industry
representative or other). Possibility to provide an answer to explain the “other” as a profession was not
provided in the survey. While cognizant of the potential for an overrepresentation of pro-vaccination
HCPs among the survey subjects, we found it useful to collect their structured feedback on LCI as it
could add value to the challenges and opportunities in the implementation of LCI. Even though we
did not collect information on survey subjects’ nationality or country of clinical practice, although
multiple nationalities from both developed and developing regions of the world attended the European
conference. We assumed proportional representation among those who attended the symposium at
which the survey was conducted.
2.2. Survey Administration
The survey was conducted on 23 May 2017 just after the symposium presentations and prior
to the open Q&A. The topic of LCI was relatively new for the ESPID audience composed mainly of
pediatricians treating only children, and therefore it was of interest to gauge their view on the life-course
approach. This survey was performed after the presentations to make sure participants had understood
what LCI was about even though this could have introduced a positive bias. Each participant was
given an electronic voting pad to interactively answer survey questions. The survey instrument
consisted of multiple-choice questions administered in English and aimed to collect data on HCP
perspectives on LCI. The survey assessed whether LCI was a priority for the participants, their views
on LCI as part of a healthy lifestyle, their willingness to spread awareness about LCI and to engage
with other health care specialists to discuss LCI. The survey also assessed participants’ perspective on
possible barriers to implement LCI and the role of industry in spreading awareness about LCI. Survey
questions were developed by the panel of speakers from various health care backgrounds including an
epidemiologist, a public health expert, a pediatrician and an anthropologist. The intent was not to
achieve a generalizable outcome but to gather insights and the immediate reaction of the international
audience of HCPs.
The ARS used for the real-time survey was the OMBEA response system (OMBEA Ltd., Covent
Garden, London, UK) [17].
2.3. Survey Questions, Data Collection and Statistical Analysis
The electronic questionnaire aimed to highlight HCP insights related to LCI based on three topics
of interest, namely LCI perceptions and role, challenges for LCI, and the role of industry. First, LCI
perceptions and role were evaluated by asking the following questions (1) Is life-course immunization
a priority for you? (2) Are you ready to discuss life-course immunization with your patients and
recommend it for the entire family? (3) Are you willing to engage with other HCPs (specialists) to
spread knowledge about the importance of vaccination for all ages? and (4) Do you think it is useful
to frame life-course immunization as part of a healthy lifestyle (together with diet, physical exercise,
smoking cessation)? Second, challenges for LCI were evaluated by asking the following questions
(1) In your profession, what do you encounter as the main reason for vaccine hesitancy? and (2) What
do you think is the main barrier to achieving high coverage at all ages? Third, the role of industry
was evaluated through the following questions (1) Do you think that the industry should be an active
partner? and (2) In addition to supplying vaccines, what should industry prioritize to stimulate
life-course immunization?
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Data collected from the real-time electronic questionnaire were analyzed and presented live as
overall results, while post-event analyses were conducted by profession. Descriptive statistics were
presented using the numbers and percentages of responses for each question. The overall results of
the votes to each question were visible to the participants and to the faculty of the symposium which
supported the live discussion on LCI. Representatives from the industry who participated in the survey
were excluded from the analysis since the objective of the research was to understand the perspective
of HCPs. Not all participants answered all questions and therefore the number of responses by each
profession was different.
3. Results
A total of 222 HCPs from various medical backgrounds including pediatricians (n = 104), infectious
disease specialists (n = 40), public health professionals (n = 39) and others (n = 39) who attended the
symposium were surveyed.
3.1. LCI Perceptions and Role
Among all surveyed participants, 77.4%–88.6% indicated that LCI was a priority. A few participants
indicated that they did not know about LCI, while 10.0%–22.6% indicated that childhood vaccination
was still the priority for them (Figure 1).
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needing some support (23.7%; Figure 2).
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Figure 3. Are you willing to engage with other HCPs (specialists) to spread knowledge about the
impo tance of vaccinat on for all a es? HCP (specialists) refers to HCPs from other health car
specialties in addition to their own profession. HCP, health care professional. Since all participants did
not answer all questions, the number of responses by each profession was different from the overall
number of participants in each professional category.
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A clear majority of participants “strongly agreed” or “agreed” on the need to position LCI as
part of a healthy lifestyle together with diet, physical exercise and smoking cessation (91.0%–100.0%;
Figure 4).
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Figure 4. Do you think it is useful to frame life-course immunization as part of a healthy lifestyle
(together with diet, physical exercise, smoking cessation)? Since all participants did not answer all
questions, the number of responses by each profession was different from the overall number of
participants in each professional category.
3.2. Challenges for LCI
Participants indicated that they encounter vaccine hesitancy in their practice and the main
reasons for this were safety concerns about vaccines (23.3%–43.3%), negative influence by social media
(18.2%–36.7%) and insufficient disease awareness in parents/individuals who are involved in making
decisions about vaccination (13.3%–28.8%; Figure A1).
Vaccine hesitancy was not the main barrier to achieving optimal vaccination coverage levels as
only 9.7%–15.2% of participants indicated that it is an impediment in the context of LCI. Other barriers
to achieving optimal vaccination coverage are insufficient recommendations by vaccine providers
(12.9%–33.3%), insufficient government recommendations (15.2%–41.9%) and insufficient budget
allocated to LCI (6.1%–21.7%; Figure A2).
3.3. The Role of Industry
Most participants indicated that vaccine manufacturers should play an active role in supporting
LCI, with 66.7%–80.8% agreeing that their role should be more active, while 7.7%–24.2% disagreed,
and 3.7%–11.5% indicated that they did not know what role the industry should play (Figure A3).
When asked about the initiatives to be prioritized by vaccine manufacturers, participants indicated
educational activities (35.3%–57.7%) as the most important, followed by access to scientific information
and innovation (26.9%–52.9%), addressing vaccine confidence/hesitancy, (2.9%–15.4%), and others
(0.0–8.8%; Figure A4).
4. Discussion
We conducted an ARS-based survey to investigate HCP perspectives on LCI. By surveying an
opportunistic sample of participants from various health care backgrounds, we were able to gai
insights from the frontline vac in tors. We gained firsthand knowled e about the import nce f LCI
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among HCPs, the problems HCPs face in implementing LCI and the role of industry in supporting
HCPs in implementing LCI. The key message of our survey is provided in Figure 5.Vaccines 2020, 8, x FOR PEER REVIEW 8 of 14 
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p rticipated in individual a foc s group discussions in 2018 [11]. Individual an focus group
responses were analyzed following narrative an lysis principles. Uncertainty surrounding curre t
immunization guidelines, cost of vaccines, recurring vaccine stock shortages and misinformation about
Vaccines 2020, 8, 185 8 of 12
vaccines were all highlighted as challenges for the frontline HCPs [11]. These results emphasize the
need to support vaccinators in their role to ensure that they can continue delivering on the success of
vaccination programs and integrate the LCI strategy.
We found that participants viewed the need for vaccine manufacturers to play an active role in
educating HCPs and other stakeholders in order to stimulate dialogue around the need for LCI. Overall,
this survey shows the need for all stakeholders involved in the process of vaccination to work together
to ensure that people may have long and healthy lives through LCI. This is in line with previous
publications which recommend a multi-disciplinary approach involving all relevant stakeholders
to ensure the successful implementation of LCI [11,12]. As an example, a similar cooperative
approach achieved success in Italy, where a multi-disciplinary partnership of medical scientific societies
representing public health, primary care and pediatrics successfully collaborated to produce three
consecutive editions of the “Lifetime Immunization Schedule” [23]. An implication of this result
is that industry could facilitate knowledge-sharing initiatives about LCI through multi-disciplinary
partnerships with HCPs and other relevant stakeholders.
In this survey, vaccine hesitancy was not seen as the main barrier in the implementation of LCI.
However, vaccine hesitancy is commonly documented in literature as a barrier to immunization [24,25].
As such, vaccine hesitancy deserves attention, especially since the WHO considers it a major threat
to global health [10]. The WHO states that vaccine hesitancy is a phenomenon in the developed
and developing countries alike as evidenced from the reemergence of infectious diseases which had
previously been eradicated or controlled [26]. These results warrant the need for further research to
understand the importance of vaccine hesitancy as a major factor affecting global health and to better
understand its role as a barrier to LCI implementation.
Strengths of this research include that survey participants came from both the developed and
the developing regions of the world and, as such, results from this study could provide insights into
transferability to other settings, which is in line with results from a prior study by Wiot et al. [11].
Furthermore, this paper shares HCP insights on LCI which may be an important addition to the
presently available evidence on LCI. This is because such survey data are seldom published and
occasionally overlooked for programmatic issues of implementing health care interventions.
We acknowledge certain limitations in our survey administration, and therefore the findings may
not be generalizable to the wider group of HCPs. This can be partly attributed to the small sample
size of the groups surveyed. Attendance to this symposium at a conference on pediatric infectious
disease followed by the survey being conducted after the speakers presented their perspective on LCI
implies selection bias that would drive answers towards a more positive trend to the topics/questions.
Stratified analysis beyond profession or assessment for possible biases would not be possible due the
small sample size of each stratum. Such an exploratory in-depth analysis is also not logistically feasible
during the limited cross-sectional timeframe to gather data through an ARS-based system amidst
an international conference. The majority of conference attendees were from developed European
countries. This could lead to various biases, since opinions of HCPs from developed countries could
be different than those from developing countries. Another limitation of this study is that LCI is not a
defined entity and the overall benefits of the approach may depend on the specifics of the immunization
program such as the vaccines being considered, immunization schedules, number of doses, population
characteristics and health economic evaluations. Lastly, health economic evaluations are increasingly
important to compare immunization programs against each other, and the importance of such research
was not evaluated in the survey.
5. Conclusions
This survey aimed to capture HCP perspectives on LCI and understand the barriers they faced
in LCI implementation and the role of industry in supporting HCPs to implement LCI. Our findings
suggest that LCI is viewed as a priority by HCPs involved in the vaccination journey and there is
agreement among HCPs to position LCI together with diet and physical exercise to achieve a healthy
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lifestyle. The results of this survey suggest a willingness of HCPs to work together to make LCI a
gateway to ‘healthy aging’ for all people. Simultaneously, the results also shed light on various barriers
to vaccination such as lack of provider and government recommendations, insufficient infrastructure
and insufficient budget ahead of vaccine hesitancy. We found that education and information campaigns
for HCPs and patients could have a tangible impact on the implementation of LCI. Our ARS-based,
cross-sectional survey of a global sample of HCPs offers an innovative way to capture insights that
could instigate further research to analyze how LCI is perceived by vaccine providers. The results of
such studies could further support health care policy makers to develop more comprehensive and
effective public health solutions.
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